A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
The UN later confirmed that Russia was planning to limit registration of ships to the port of Pivdennyi until all parties agreed to unblock the transit of Russian ammonia. The FSB said it had discovered an "intelligence action" that had compromised the phones of Russians as well as diplomats from Israel, Syria, China and NATO members and claimed that Apple had worked with US intelligence agencies such as the National Security Agency in compromising numerous iPhones. Apple did not comment on whether its products in Russia had been hacked but denied working with authorities to compromise its devices. The Pentagon said that it would buy Elon Musk's Starlink satellite service for Ukraine to ensure the continued effectivity of communications in the country. The US State Department said it was revoking the visas of Russian nuclear inspectors, denying pending applications for new monitors and canceling standard clearances for Russian aircraft to enter US airspace in retaliation for Russia's suspension of its participation in the New START treaty. It also said it would no longer notify Russia of any updates on the status or location of "treaty-accountable items" like missiles and launchers. The Swiss National Council voted down, 98–75, a parliamentary initiative put forward by a committee that would have specifically authorized the transfer of Swiss-made arms to Ukraine. Its opponents claimed the proposal was a violation of the country's longstanding policy of neutrality.
=== Books === Nanotechnology in Drug Delivery (2008) ISBN 978-0387776675 Silk: Properties, Production and Uses (2012) ISBN 978-1621006923 Sustainable Uses of Byproducts from Silk Processing (2021) ISBN 978-3527347865
Compared to amorphous structures, semi-crystalline structures lead to a higher stiffness, density, melting temperature and higher resistance of a polymer. Cross-linked polymers: Wide-meshed cross-linked polymers are elastomers and cannot be molten (unlike thermoplastics); heating cross-linked polymers only leads to decomposition. Thermoplastic elastomers, on the other hand, are reversibly "physically crosslinked" and can be molten. Block copolymers in which a hard segment of the polymer has a tendency to crystallize and a soft segment has an amorphous structure are one type of thermoplastic elastomers: the hard segments ensure wide-meshed, physical crosslinking.
== Function == The architecture of a dry shipper encompasses two primary components: an internal canister and an external protective shell. The inner canister, designed to hold biological specimens, is positioned within the vapor phase of the liquid nitrogen. This configuration ensures that the specimens are maintained at temperatures below -150 °C (302 °F) for prolonged periods. A distinctive feature of dry shippers is their ability to avert direct contact between samples and liquid nitrogen, reducing risks of contamination and ensuring consistent cryogenic conditions during transit.
Sources: en.wikipedia.org
Semi-closed rebreather technology is sometimes used in diver carried surface supplied gas extenders, mainly to reduce helium use. Some units also function as an emergency gas supply using on-board bailout cylinders: The US Navy MK29 rebreather can extend the duration of the Flyaway Mixed Gas System diving operations by five times while retaining the original mixed-gas storage footprint on the support ship. The Soviet IDA-72 semi-closed rebreather has a scrubber endurance of 4 hours on surface supply, and bailout endurance at 200m of 40 minutes on on-board gas. The US Navy Mark V Mod 1 heliox mixed gas helmet has a scrubber canister mounted on the back of the helmet and an inlet gas injection system which recirculates the breathing gas through the scrubber to remove carbon dioxide and thereby conserve helium. The injector nozzle would blow 11 times the volume of the injected gas through the scrubber.
== Usage == AUFS is an arbitrary unit of the maximum ultraviolet or visible light absorbance intensity measured by a detector. It can be used in chemical analysis to quantify components in a mixture, as each component's integrated peak area corresponds to their relative abundance. AUFS is given as a number ranging from 0 to 1, where a measurement of 1 AUFS indicates an absorbance reading of 1 at full deflection.
=== Early DNA sequencing methods === The first method for determining DNA sequences involved a location-specific primer extension strategy established by Ray Wu, a Chinese-born American geneticist, at Cornell University in 1970. DNA polymerase catalysis and specific nucleotide labeling, both of which figure prominently in current sequencing schemes, were used to sequence the cohesive ends of lambda phage DNA. Between 1970 and 1973, Wu, scientist Radha Padmanabhan, and colleagues demonstrated that this method can be employed to determine any DNA sequence using synthetic location-specific primers. Walter Gilbert, a biochemist, and Allan Maxam, a molecular geneticist, at Harvard also developed sequencing methods, including one for "DNA sequencing by chemical degradation". In 1973, Gilbert and Maxam reported the sequence of 24 basepairs using a method known as wandering-spot analysis. Advancements in sequencing were aided by the concurrent development of recombinant DNA technology, allowing DNA samples to be isolated from sources other than viruses. Two years later in 1975, Frederick Sanger, a biochemist, and Alan Coulson, a genome scientist, developed a method to sequence DNA. The technique known as the "Plus and Minus" method, involved supplying all the components of the DNA but excluding the reaction of one of the four bases needed to complete the DNA. In 1976, Gilbert and Maxam, invented a method for rapidly sequencing DNA while at Harvard, known as the Maxam–Gilbert sequencing.
Following the sale of lots, Knoxville's leaders set about constructing a courthouse and jail. A garrison of federal soldiers, under the command of David Henley, erected a blockhouse in Knoxville in 1792. The Cowan brothers, Nathaniel and Samuel, opened the city's first general store in August 1792, and John Chisholm's tavern was in operation by December 1792. The city's first newspaper, the Knoxville Gazette, was established by George Roulstone in November 1791. In 1794, Blount College, the forerunner of the University of Tennessee, was chartered, with Samuel Carrick as its first president. Carrick also established the city's first church, the First Presbyterian Church, though a building wasn't constructed until 1816.
== Publications == AMP co-owns The Journal of Molecular Diagnostics (JMD) with the American Society for Investigative Pathology. First published in 1999, JMD is the highest ranked journal in its field, with an Impact Factor rating of 5.341 in 2021. Its focus includes original research on advances in molecular diagnostic medicine in oncology, infectious diseases, hematopathology, inherited diseases, clinical informatics, as well as review articles. AMP members receive complementary online access to the journal with their membership, discounts on publication fees, and AMP makes its practice guidelines available free of charge. In addition, AMP working groups also collaborate with colleagues from other scholarly societies on reports appearing in publications other than JMD.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.